Boehringer Ingelheim has become the latest drugmaker to turn to Sino Biopharmaceutical’s research team, inking a deal worth up to $7.4bn that spans multiple oncology modalities.
The license agreement sees Boehringer pay $358m upfront to cover six biologic preclinical programmes. Sino is also in line for up to $7bn in milestone-based payments, alongside royalties on sales from any drugs commercialised via the partnership.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Sino will be in charge of undertaking early development, with Boehringer coming on board after agreed clinical milestones are met. The German drugmaker can then exercise its option for exclusive development, manufacturing and commercialisation rights. For four programmes, it will have rights outside China, Hong Kong, and Macau; it will have global rights for the other two programmes.
Five of the programmes will come from Sino’s subsidiary LaNova Medicines, with the remaining asset emerging from Beijing Tide – another subsidiary of the Chinese group. Sino bought LaNova for $951m in July 2025.
The two companies did not disclose the indications of the programmes, though they did confirm that next-generation cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TCE) technologies will form the basis of the collaboration. ADCs have become a frequent point of focus in both M&A and licensing deals this year given the modality’s targeted approach in multiple cancers. The largest of these was an up to $15bn deal between Roche and China’s Hansoh Pharma last month. TCEs, a targeted type of immunotherapy, are also moving beyond their early success in blood cancers.
Boehringer’s innovation unit head, Paola Casarosa, said: “Our partnership with Sino Biopharma brings together complementary science to broaden our development portfolio of ADCs and TCEs. It puts our China strategy into action by connecting innovation from China with our global research and development capabilities.”
The deal comes soon after Boehringer opened a new R&D centre in Shanghai in October.
Boehringer is far from the only Western company to venture to Sino in search of pipeline bolstering. Sanofi, GSK, and AstraZeneca have all signed licensing deals with the Chinese pharma in 2026. However, none of these topped $2bn, meaning Boehringer’s was the largest by potential deal value.
A 2025 report by GlobalData, parent company of Pharmaceutical Tehcnology, demonstrated that China-based companies were responsible for 20% of drugs in development globally. It is likely that the percentage has since risen given China’s R&D boom.
The Chinese government has since unveiled an ambitious five-year plan for its biomedical industry, as the country looks to cement its role as a powerhouse in the global drug innovation landscape. As part of the strategy, China wants to increase its share of originally innovated drugs. By 2030, the nation aims to make and develop 25% of global first-in-class drugs.
ADC content on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
